This model was utilized to explore the potential response in the patients from NCT02259621 trial that implemented neoadjuvant nivolumab therapy before surgical resection of the NSCLC tumors and showed the relative importance of TMB versus MHC/antigen binding affinity. This evidence concerns the gene HLA-C and non-small cell lung carcinoma.